CytomX Therapeutics, Inc. CTMX
Biotechnology: Pharmaceutical Preparations · IPO 2015 · data as of November 13, 2026
CytomX Therapeutics, Inc. (CTMX) is a healthcare company listed in the US with a market value of about $445M. In the twelve months to September 30, 2026 it had revenue of $14M and net income of -$88M, a net margin of -630.3%.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 2% a year, a 5-year average ROIC of -95%.
About CytomX Therapeutics
CytomX Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2015. Revenue went from $5M in 2014 to $76M in 2025, growth of about 27.9% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 110% over three years (dilution for shareholders). It spends 90% of revenue on research and development.
Score: 0.8 / 5
Checks passed
- 3-year revenue growth above 10% a year
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14M | $76M | $138M | $101M | $53M | $37M | $68M | $27M | $60M | $72M | $15M |
| Net income | -$88M | -$17M | $32M | -$569000 | -$99M | -$116M | -$65M | -$133M | -$85M | -$43M | -$59M |
| Free cash flow | -$51M | -$76M | -$87M | -$57M | -$113M | -$121M | $3M | -$144M | -$79M | $169M | -$4M |
| EPS (diluted) | $-0.50 | $-0.15 | $0.38 | $-0.01 | $-1.51 | $-1.81 | $-1.40 | $-2.93 | $-2.03 | $-1.16 | $-1.63 |
| Net margin | -630.3% | -22.8% | 23.1% | -0.6% | -186.8% | -310.5% | -94.7% | -493.7% | -142.2% | -60.2% | -391.5% |
| ROIC | — | -17.1% | 278.0% | — | — | -547.0% | -387.9% | -265.3% | -45.3% | -65.4% | -75.9% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 8 analysts is $12.38, 507% above the current price; targets range from $5.00 to $16.00; the consensus rating is “Strong buy”; expected EPS is $-0.39 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does CytomX Therapeutics pay a dividend?
Not currently.
Is CytomX Therapeutics a good stock to buy?
We do not give buy or sell advice. CytomX Therapeutics scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.